Research progress on the correlation between small intestinal bacterial overgrowth and non-erosive gastroesophageal reflux disease_West China Medical Journal

Authors：

TANG Shilin ¹ , FENG Caiju ¹ , ZHANG Xiumei ¹ , XU Zhihong ¹ , XIONG Xin ² ,  HE Suyu ^1,2

1. Graduate School of Zunyi Medical University, Zunyi, Guizhou 563000, P. R. China;
2. The Fourth Department of Digestive Disease Center, Suining Central Hospital, Suining, Sichuan 629000, P. R. China;

Corresponding author：

HE Suyu, Email: hesuyu2009@163.com

Keywords：

small intestinal bacterial overgrowth; non-erosive gastroesophageal reflux disease; intestinal microecology; inflammatory reaction; gastrointestinal motility disorder

DOI：

10.7507/1002-0179.202307101

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Non-erosive gastroesophageal reflux disease (NERD) refers to a disease with symptoms such as acid reflux, heartburn and pathological reflux, but no significant esophageal mucosal damage under endoscopy. Its pathogenesis may be related to factors such as lower esophageal sphincter dysfunction, weakened esophageal clearance ability, visceral hypersensitivity, and disordered intestinal microecology, but the specific mechanism is still unclear. Small intestinal bacterial overgrowth (SIBO) is a common intestinal flora disorder syndrome. A number of studies have shown that SIBO has a certain correlation with NERD, and SIBO may be involved in the occurrence and development of NERD through mechanisms such as inflammatory response, gas production, and increased short-chain fatty acids. Therefore, this article reviews the correlation between NERD and SIBO, aiming to provide new ideas for the diagnosis and treatment of NERD.

Citation： TANG Shilin, FENG Caiju, ZHANG Xiumei, XU Zhihong, XIONG Xin, HE Suyu. Research progress on the correlation between small intestinal bacterial overgrowth and non-erosive gastroesophageal reflux disease. West China Medical Journal, 2024, 39(1): 129-135. doi: 10.7507/1002-0179.202307101 Copy

1.	Zhang M, Chen M, Peng S, et al. The Rome Ⅳ versus Rome Ⅲ criteria for heartburn diagnosis: a comparative study. United European Gastroenterol J, 2018, 6(3): 358-366.
2.	Khan Z, Alastal Y, Khan MA, et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol Res Pract, 2018, 2018: 6417526.
3.	Fass R, Boeckxstaens GE, El-Serag H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers, 2021, 7(1): 55.
4.	El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2014, 63(6): 871-880.
5.	Zheng Z, Shang Y, Wang N, et al. Current advancement on the dynamic mechanism of gastroesophageal reflux disease. Int J Biol Sci, 2021, 17(15): 4154-4164.
6.	赵新胜, 买买提·依斯热依力, 克力木·阿不都热依木. 非糜烂性食管炎和内脏高敏感研究新进展. 中华胃食管反流病电子杂志, 2019, 6(4): 211-215.
7.	赵新胜. SP、CGRP 及炎症因子在非糜烂性食管炎发生中的作用研究. 乌鲁木齐: 新疆医科大学, 2020.
8.	王轶, 朱生樑. 非糜烂性反流病相关危险因素分析. 国际消化病杂志, 2018, 38(1): 32-36.
9.	余杨, 马颖才. 小肠细菌过度生长的病因及危险因素研究进展. 山东医药, 2021, 61(33): 99-103.
10.	赵飞燕, 崔立红. 小肠细菌过度生长与胃食管反流病的相关性分析. 解放军医学杂志, 2022, 48(9): 1076-1080.
11.	Pimentel M, Saad RJ, Long MD, et al. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol, 2020, 115(2): 165-178.
12.	严明, 李小峰. 小肠细菌过度生长诊断和治疗研究进展. 胃肠病学和肝病学杂志, 2020, 29(11): 1301-1304.
13.	黄燕妮, 王承党. 小肠细菌过度生长与功能性消化不良的关系. 胃肠病学和肝病学杂志, 2016, 25(3): 241-244.
14.	Liu XJ, Xie WR, Wu LH, et al. Changes in oral flora of patients with functional dyspepsia. Sci Rep, 2021, 11(1): 8089.
15.	Chen B, Kim JJ, Zhang Y, et al. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol, 2018, 53(7): 807-818.
16.	Kim BT, Kim KM, Kim KN. The effect of ursodeoxycholic acid on small intestinal bacterial overgrowth in patients with functional dyspepsia: a pilot randomized controlled trial. Nutrients, 2020, 12(5): 1410.
17.	Tziatzios G, Giamarellos-Bourboulis EJ, Papanikolaou IS, et al. Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. Med Hypotheses, 2017, 106: 26-32.
18.	Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol, 2014, 20(10): 2482-2491.
19.	Zhao DY, Qi QQ, Long X, et al. Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome. Physiol Int, 2019, 106(3): 225-235.
20.	Park JM, Chi KC. Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease. Ann Surg Treat Res, 2018, 95(2): 94-99.
21.	Haworth JJ, Boyle N, Vales A, et al. The prevalence of intestinal dysbiosis in patients referred for antireflux surgery. Surg Endosc, 2021, 35(12): 7112-7119.
22.	阿布拉江·米吉提, 买买提·依斯热依力, 克力木·阿不都热依木. 炎症因子及氧化应激在 GERD 食管黏膜炎症损伤发生中的作用. 中华胃食管反流病电子杂志, 2018, 5(3): 130-134.
23.	李莉, 展玉涛, 郭宝娜, 等. 气体反流在难治性胃食管反流病中作用. 临床军医杂志, 2018, 46(6): 624-627.
24.	Piche T, des Varannes SB, Sacher-Huvelin S, et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology, 2003, 124(4): 894-902.
25.	陈家坤. 背俞指针疗法对 GERD 大鼠 SCF-c-kit-ICC 信号通路的影响. 南宁: 广西中医药大学, 2017.
26.	Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest, 2011, 41(4): 380-386.
27.	丁文京. 小肠细菌过度生长和胃食管反流病. 中华胃食管反流病电子杂志, 2020, 7(3): 182-187.
28.	吴斌, 王涛. 抑制小肠细菌过生长对焦虑抑郁症患者的影响. 河南医学研究, 2019, 28(14): 2536-2538.
29.	Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res, 2012, 18(8): 2138-2144.
30.	Hasan A, Hasan LK, Schnabl B, et al. Microbiome of the aerodigestive tract in health and esophageal disease. Dig Dis Sci, 2021, 66(1): 12-18.
31.	程鹏, 王亚雷, 许建明, 等. IL-1β和 IL-1RN 基因多态性与胃食管反流病相关性的研究. 安徽医科大学学报, 2012, 47(4): 442-446.
32.	Inada T, Hamano N, Yamada M, et al. Inducible nitric oxide synthase and tumor necrosis factor- alpha in delayed gastric emptying and gastrointestinal transit induced by lipopolysaccharide in mice. Braz J Med Biol Res, 2006, 39(11): 1425-1434.
33.	戴璐, 汪怡, 薛建国, 等. 消化道微生物菌群与胃食管反流病相关研究进展. 国际检验医学杂志, 2022, 43(24): 3053-3057.
34.	吾布力卡斯木·吾拉木, 巴突尔·艾克木, 买买提·依斯热依力, 等. 不同亚型胃食管反流病食管黏膜下层炎症因子变化特点研究. 中华胃食管反流病电子杂志, 2018, 5(3): 97-101.
35.	陆会飞, 牛小平. 神经肽参与 NERD 内脏高敏感外周机制的研究进展. 胃肠病学和肝病学杂志, 2016, 25(9): 1071-1074.
36.	陈雅菲, 范钟麟, 王学红. 小肠细菌过度生长在肠易激综合征中的研究进展. 胃肠病学, 2010, 15(5): 309-311.
37.	Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci, 2004, 49(1): 84-87.
38.	赵倩, 赵艳, 殷燕, 等. 血清 GABA、BDNF、5-HT、DA 及 NE 在胃食管反流病中的表达及临床意义. 贵州医科大学学报, 2023, 48(2): 193-199.
39.	Piche T, Zerbib F, Varannes SB, et al. Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol, 2000, 278(4): G578-G584.
40.	Chojnacki C, Popławski T, Konrad P, et al. Antimicrobial treatment improves tryptophan metabolism and mood of patients with small intestinal bacterial overgrowth. Nutr Metab (Lond), 2022, 19(1): 66.
41.	秦宇, 张永鹤. 犬尿氨酸代谢通路对抑郁症的影响机制研究进展. 中国药理学通报, 2020, 36(12): 1640-1644.
42.	唐祎昀. Itaconate 对β2 微球蛋白诱导抑郁和焦虑样行为的拮抗作用及其犬尿氨酸通路调控机制. 衡阳: 南华大学, 2020.
43.	Choi JM, Yang JI, Kang SJ, et al. Association between anxiety and depression and gastroesophageal reflux disease: results from a large cross-sectional study. J Neurogastroenterol Motil, 2018, 24(4): 593-602.
44.	Wang Y, Zhou B, Fang S, et al. Dynorphin participates in interaction between depression and non-erosive reflux disease. Esophagus, 2023, 20(1): 158-169.
45.	Chen X, Li P, Wang F, et al. Psychological results of 438 patients with persisting gastroesophageal reflux disease symptoms by symptom checklist 90-revised questionnaire. Euroasian J Hepatogastroenterol, 2017, 7(2): 117-121.
46.	Oh JH, Kim TS, Choi MG, et al. Relationship between psychological factors and quality of life in subtypes of gastroesophageal reflux disease. Gut and Liver, 2009, 3(4): 259-265.
47.	樊皓, 苏有媛, 王晓迪, 等. 胃食管反流病与胃肠道微生态关系的研究进展. 中国微生态学杂志, 2022, 34(4): 489-492.
48.	Yao Q, Yu Z, Meng Q, et al. The role of small intestinal bacterial overgrowth in obesity and its related diseases. Biochem Pharmacol, 2023, 212: 115546.
49.	Wijarnpreecha K, Werlang ME, Watthanasuntorn K, et al. Obesity and risk of small intestine bacterial overgrowth: a systematic review and meta-analysis. Dig Dis Sci, 2020, 65(5): 1414-1422.
50.	Playford RJ, Choudhry N, Kelly P, et al. Effects of bovine colostrum with or without egg on in vitro bacterial-induced intestinal damage with relevance for SIBO and infectious diarrhea. Nutrients, 2021, 13(3): 1024.
51.	Bona MD, Torres CHM, Lima SCVC, et al. Intestinal barrier permeability in obese individuals with or without metabolic syndrome: a systematic review. Nutrients, 2022, 14(17): 3649.
52.	Bohm M, Shin A, Teagarden S, et al. Risk factors associated with upper aerodigestive tract or coliform bacterial overgrowth of the small intestine in symptomatic patients. J Clin Gastroenterol, 2020, 54(2): 150-157.
53.	Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology, 2017, 151(4): 363-374.
54.	Roland BC, Ciarleglio MM, Clarke JO, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol, 2015, 49(7): 571-576.
55.	Miron I, Dumitrascu DL. Gastrointestinal motility disorders in obesity. Acta Endocrinol (Buchar), 2019, 15(4): 497-504.
56.	Bravo-San Pedro JM, Sica V, Martins I, et al. Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity. Cell Metab, 2019, 30(4): 754-767. e9.
57.	Chen K, Hu M, Tang M, et al. Oligosaccharide and short-chain fatty acid: a double-edged sword in obese mice by regulating food intake and fat synthesis. Food Res Int, 2022, 159: 111619.
58.	Tirosh A, Calay ES, Tuncman G, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med, 2019, 11(489): eaav0120.
59.	Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut, 2018, 67(3): 430-440.
60.	Herbella FA, Sweet MP, Tedesco P, et al. Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment. J Gastrointest Surg, 2007, 11(3): 286-290.
61.	何源, 段志军. 胃食管反流病与肥胖: 病理生理学和治疗. 大连医科大学学报, 2023, 45(2): 97-105.
62.	许欢, 虎月燕, 张文龙, 等. 幽门螺杆菌感染与小肠细菌过度生长的相关性研究进展. 重庆医学, 2019, 48(9): 1564-1568.
63.	Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun, 2020, 11(1): 362.
64.	Dore MP, Pes GM, Bassotti G, et al. Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett’s esophagus in Nothern Sardinia. Scand J Gastroenterol, 2016, 51(11): 1281-1287.
65.	Manes G, Mosca S, Laccetti M, et al. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Scand J Gastroenterol, 1999, 34(7): 658-662.
66.	张茹, 李园, 马金霞, 等. 长期维持质子泵抑制剂治疗对老年人小肠细菌过度生长的影响分析. 中华内科杂志, 2020, 59(9): 706-710.
67.	Drall KM, Tun HM, Kozyrskyj AL. Commentary: the influence of proton pump inhibitors on the fecal microbiome of infants with gastroesophageal reflux-a prospective longitudinal interventional study. Front Cell Infect Microbiol, 2018, 8: 430.
68.	Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol, 2015, 6(6): e89.
69.	Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med, 2014, 34(4): 771-785.
70.	Macke L, Schulz C, Koletzko L, et al. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther, 2020, 51(5): 505-526.

1. Zhang M, Chen M, Peng S, et al. The Rome Ⅳ versus Rome Ⅲ criteria for heartburn diagnosis: a comparative study. United European Gastroenterol J, 2018, 6(3): 358-366.
2. Khan Z, Alastal Y, Khan MA, et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol Res Pract, 2018, 2018: 6417526.
3. Fass R, Boeckxstaens GE, El-Serag H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers, 2021, 7(1): 55.
4. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2014, 63(6): 871-880.
5. Zheng Z, Shang Y, Wang N, et al. Current advancement on the dynamic mechanism of gastroesophageal reflux disease. Int J Biol Sci, 2021, 17(15): 4154-4164.
6. 赵新胜, 买买提·依斯热依力, 克力木·阿不都热依木. 非糜烂性食管炎和内脏高敏感研究新进展. 中华胃食管反流病电子杂志, 2019, 6(4): 211-215.
7. 赵新胜. SP、CGRP 及炎症因子在非糜烂性食管炎发生中的作用研究. 乌鲁木齐: 新疆医科大学, 2020.
8. 王轶, 朱生樑. 非糜烂性反流病相关危险因素分析. 国际消化病杂志, 2018, 38(1): 32-36.
9. 余杨, 马颖才. 小肠细菌过度生长的病因及危险因素研究进展. 山东医药, 2021, 61(33): 99-103.
10. 赵飞燕, 崔立红. 小肠细菌过度生长与胃食管反流病的相关性分析. 解放军医学杂志, 2022, 48(9): 1076-1080.
11. Pimentel M, Saad RJ, Long MD, et al. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol, 2020, 115(2): 165-178.
12. 严明, 李小峰. 小肠细菌过度生长诊断和治疗研究进展. 胃肠病学和肝病学杂志, 2020, 29(11): 1301-1304.
13. 黄燕妮, 王承党. 小肠细菌过度生长与功能性消化不良的关系. 胃肠病学和肝病学杂志, 2016, 25(3): 241-244.
14. Liu XJ, Xie WR, Wu LH, et al. Changes in oral flora of patients with functional dyspepsia. Sci Rep, 2021, 11(1): 8089.
15. Chen B, Kim JJ, Zhang Y, et al. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol, 2018, 53(7): 807-818.
16. Kim BT, Kim KM, Kim KN. The effect of ursodeoxycholic acid on small intestinal bacterial overgrowth in patients with functional dyspepsia: a pilot randomized controlled trial. Nutrients, 2020, 12(5): 1410.
17. Tziatzios G, Giamarellos-Bourboulis EJ, Papanikolaou IS, et al. Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. Med Hypotheses, 2017, 106: 26-32.
18. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol, 2014, 20(10): 2482-2491.
19. Zhao DY, Qi QQ, Long X, et al. Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome. Physiol Int, 2019, 106(3): 225-235.
20. Park JM, Chi KC. Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease. Ann Surg Treat Res, 2018, 95(2): 94-99.
21. Haworth JJ, Boyle N, Vales A, et al. The prevalence of intestinal dysbiosis in patients referred for antireflux surgery. Surg Endosc, 2021, 35(12): 7112-7119.
22. 阿布拉江·米吉提, 买买提·依斯热依力, 克力木·阿不都热依木. 炎症因子及氧化应激在 GERD 食管黏膜炎症损伤发生中的作用. 中华胃食管反流病电子杂志, 2018, 5(3): 130-134.
23. 李莉, 展玉涛, 郭宝娜, 等. 气体反流在难治性胃食管反流病中作用. 临床军医杂志, 2018, 46(6): 624-627.
24. Piche T, des Varannes SB, Sacher-Huvelin S, et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology, 2003, 124(4): 894-902.
25. 陈家坤. 背俞指针疗法对 GERD 大鼠 SCF-c-kit-ICC 信号通路的影响. 南宁: 广西中医药大学, 2017.
26. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest, 2011, 41(4): 380-386.
27. 丁文京. 小肠细菌过度生长和胃食管反流病. 中华胃食管反流病电子杂志, 2020, 7(3): 182-187.
28. 吴斌, 王涛. 抑制小肠细菌过生长对焦虑抑郁症患者的影响. 河南医学研究, 2019, 28(14): 2536-2538.
29. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res, 2012, 18(8): 2138-2144.
30. Hasan A, Hasan LK, Schnabl B, et al. Microbiome of the aerodigestive tract in health and esophageal disease. Dig Dis Sci, 2021, 66(1): 12-18.
31. 程鹏, 王亚雷, 许建明, 等. IL-1β和 IL-1RN 基因多态性与胃食管反流病相关性的研究. 安徽医科大学学报, 2012, 47(4): 442-446.
32. Inada T, Hamano N, Yamada M, et al. Inducible nitric oxide synthase and tumor necrosis factor- alpha in delayed gastric emptying and gastrointestinal transit induced by lipopolysaccharide in mice. Braz J Med Biol Res, 2006, 39(11): 1425-1434.
33. 戴璐, 汪怡, 薛建国, 等. 消化道微生物菌群与胃食管反流病相关研究进展. 国际检验医学杂志, 2022, 43(24): 3053-3057.
34. 吾布力卡斯木·吾拉木, 巴突尔·艾克木, 买买提·依斯热依力, 等. 不同亚型胃食管反流病食管黏膜下层炎症因子变化特点研究. 中华胃食管反流病电子杂志, 2018, 5(3): 97-101.
35. 陆会飞, 牛小平. 神经肽参与 NERD 内脏高敏感外周机制的研究进展. 胃肠病学和肝病学杂志, 2016, 25(9): 1071-1074.
36. 陈雅菲, 范钟麟, 王学红. 小肠细菌过度生长在肠易激综合征中的研究进展. 胃肠病学, 2010, 15(5): 309-311.
37. Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci, 2004, 49(1): 84-87.
38. 赵倩, 赵艳, 殷燕, 等. 血清 GABA、BDNF、5-HT、DA 及 NE 在胃食管反流病中的表达及临床意义. 贵州医科大学学报, 2023, 48(2): 193-199.
39. Piche T, Zerbib F, Varannes SB, et al. Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol, 2000, 278(4): G578-G584.
40. Chojnacki C, Popławski T, Konrad P, et al. Antimicrobial treatment improves tryptophan metabolism and mood of patients with small intestinal bacterial overgrowth. Nutr Metab (Lond), 2022, 19(1): 66.
41. 秦宇, 张永鹤. 犬尿氨酸代谢通路对抑郁症的影响机制研究进展. 中国药理学通报, 2020, 36(12): 1640-1644.
42. 唐祎昀. Itaconate 对β2 微球蛋白诱导抑郁和焦虑样行为的拮抗作用及其犬尿氨酸通路调控机制. 衡阳: 南华大学, 2020.
43. Choi JM, Yang JI, Kang SJ, et al. Association between anxiety and depression and gastroesophageal reflux disease: results from a large cross-sectional study. J Neurogastroenterol Motil, 2018, 24(4): 593-602.
44. Wang Y, Zhou B, Fang S, et al. Dynorphin participates in interaction between depression and non-erosive reflux disease. Esophagus, 2023, 20(1): 158-169.
45. Chen X, Li P, Wang F, et al. Psychological results of 438 patients with persisting gastroesophageal reflux disease symptoms by symptom checklist 90-revised questionnaire. Euroasian J Hepatogastroenterol, 2017, 7(2): 117-121.
46. Oh JH, Kim TS, Choi MG, et al. Relationship between psychological factors and quality of life in subtypes of gastroesophageal reflux disease. Gut and Liver, 2009, 3(4): 259-265.
47. 樊皓, 苏有媛, 王晓迪, 等. 胃食管反流病与胃肠道微生态关系的研究进展. 中国微生态学杂志, 2022, 34(4): 489-492.
48. Yao Q, Yu Z, Meng Q, et al. The role of small intestinal bacterial overgrowth in obesity and its related diseases. Biochem Pharmacol, 2023, 212: 115546.
49. Wijarnpreecha K, Werlang ME, Watthanasuntorn K, et al. Obesity and risk of small intestine bacterial overgrowth: a systematic review and meta-analysis. Dig Dis Sci, 2020, 65(5): 1414-1422.
50. Playford RJ, Choudhry N, Kelly P, et al. Effects of bovine colostrum with or without egg on in vitro bacterial-induced intestinal damage with relevance for SIBO and infectious diarrhea. Nutrients, 2021, 13(3): 1024.
51. Bona MD, Torres CHM, Lima SCVC, et al. Intestinal barrier permeability in obese individuals with or without metabolic syndrome: a systematic review. Nutrients, 2022, 14(17): 3649.
52. Bohm M, Shin A, Teagarden S, et al. Risk factors associated with upper aerodigestive tract or coliform bacterial overgrowth of the small intestine in symptomatic patients. J Clin Gastroenterol, 2020, 54(2): 150-157.
53. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology, 2017, 151(4): 363-374.
54. Roland BC, Ciarleglio MM, Clarke JO, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol, 2015, 49(7): 571-576.
55. Miron I, Dumitrascu DL. Gastrointestinal motility disorders in obesity. Acta Endocrinol (Buchar), 2019, 15(4): 497-504.
56. Bravo-San Pedro JM, Sica V, Martins I, et al. Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity. Cell Metab, 2019, 30(4): 754-767. e9.
57. Chen K, Hu M, Tang M, et al. Oligosaccharide and short-chain fatty acid: a double-edged sword in obese mice by regulating food intake and fat synthesis. Food Res Int, 2022, 159: 111619.
58. Tirosh A, Calay ES, Tuncman G, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med, 2019, 11(489): eaav0120.
59. Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut, 2018, 67(3): 430-440.
60. Herbella FA, Sweet MP, Tedesco P, et al. Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment. J Gastrointest Surg, 2007, 11(3): 286-290.
61. 何源, 段志军. 胃食管反流病与肥胖: 病理生理学和治疗. 大连医科大学学报, 2023, 45(2): 97-105.
62. 许欢, 虎月燕, 张文龙, 等. 幽门螺杆菌感染与小肠细菌过度生长的相关性研究进展. 重庆医学, 2019, 48(9): 1564-1568.
63. Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun, 2020, 11(1): 362.
64. Dore MP, Pes GM, Bassotti G, et al. Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett’s esophagus in Nothern Sardinia. Scand J Gastroenterol, 2016, 51(11): 1281-1287.
65. Manes G, Mosca S, Laccetti M, et al. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Scand J Gastroenterol, 1999, 34(7): 658-662.
66. 张茹, 李园, 马金霞, 等. 长期维持质子泵抑制剂治疗对老年人小肠细菌过度生长的影响分析. 中华内科杂志, 2020, 59(9): 706-710.
67. Drall KM, Tun HM, Kozyrskyj AL. Commentary: the influence of proton pump inhibitors on the fecal microbiome of infants with gastroesophageal reflux-a prospective longitudinal interventional study. Front Cell Infect Microbiol, 2018, 8: 430.
68. Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol, 2015, 6(6): e89.
69. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med, 2014, 34(4): 771-785.
70. Macke L, Schulz C, Koletzko L, et al. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther, 2020, 51(5): 505-526.

West China Medical Journal

Research progress on the correlation between small intestinal bacterial overgrowth and non-erosive gastroesophageal reflux disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content